|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 181.30 USD | -0.37% |
|
-0.43% | +18.56% |
| Capitalization | 26.6B 22.86B 21.42B 19.96B 36.87B 2,394B 40.11B 251B 96.73B 1,131B 99.82B 97.69B 4,134B | P/E ratio 2025 * |
16.9x | P/E ratio 2026 * | 14.6x |
|---|---|---|---|---|---|
| Enterprise value | 28.38B 24.4B 22.85B 21.3B 39.35B 2,554B 42.8B 267B 103B 1,206B 107B 104B 4,411B | EV / Sales 2025 * |
2.89x | EV / Sales 2026 * | 2.73x |
| Free-Float |
85.5% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Biogen Inc.
| 1 day | -0.37% | ||
| 1 week | -0.43% | ||
| Current month | -0.43% | ||
| 1 month | +16.58% | ||
| 3 months | +28.88% | ||
| 6 months | +36.18% | ||
| Current year | +18.56% |
| 1 week | 174.53 |  | 183.15 |
| 1 month | 153.77 | | 185.17 |
| Current year | 110.04 | | 185.17 |
| 1 year | 110.04 | | 185.17 |
| 3 years | 110.04 | | 319.76 |
| 5 years | 110.04 | | 468.55 |
| 10 years | 110.04 | | 468.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2022-11-13 | |
Robin Kramer
DFI | Director of Finance/CFO | 59 | 2025-02-28 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 58 | 2023-10-01 |
| Director | Title | Age | Since |
|---|---|---|---|
Caroline Dorsa
CHM | Chairman | 65 | 2023-06-25 |
Eric Rowinsky
BRD | Director/Board Member | 68 | 2010-03-22 |
Stephen Sherwin
BRD | Director/Board Member | 76 | 2009-12-31 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 4.3% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.37% | -0.43% | +14.91% | -37.94% | 26.6B | |
| -0.61% | -7.92% | -7.67% | -6.01% | 73.7B | |
| +0.76% | +1.01% | -34.05% | -37.65% | 58.94B | |
| +0.65% | +3.96% | +36.87% | +243.30% | 54.7B | |
| -2.32% | +64.10% | +64.10% | +64.10% | 51.57B | |
| -6.96% | -9.70% | +118.93% | +180.66% | 20.25B | |
| +2.05% | -1.86% | +35.04% | +22.00% | 20.13B | |
| -12.04% | -14.35% | +49.18% | +1,084.18% | 16.58B | |
| -1.50% | +2.26% | +155.78% | +696.11% | 14.19B | |
| -0.04% | -.--% | +55.97% | +143.80% | 14.02B | |
| Average | -2.19% | -2.47% | +48.91% | +235.25% | 35.07B | |
| Weighted average by Cap. | -0.93% | -2.40% | +28.72% | +133.77% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 9.81B 8.44B 7.9B 7.37B 13.6B 883B 14.8B 92.43B 35.69B 417B 36.83B 36.04B 1,525B | 9.3B 7.99B 7.49B 6.98B 12.89B 837B 14.02B 87.6B 33.82B 395B 34.9B 34.16B 1,445B |
| Net income | 1.54B 1.32B 1.24B 1.15B 2.13B 138B 2.32B 14.48B 5.59B 65.34B 5.77B 5.65B 239B | 1.82B 1.56B 1.46B 1.37B 2.52B 164B 2.74B 17.13B 6.61B 77.31B 6.83B 6.68B 283B |
| Net Debt | 1.78B 1.53B 1.44B 1.34B 2.47B 161B 2.69B 16.81B 6.49B 75.86B 6.7B 6.56B 277B | -1.19B -1.02B -957M -892M -1.65B -107B -1.79B -11.19B -4.32B -50.51B -4.46B -4.36B -185B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 181.30 $ | -0.37% | 1,209,961 |
| 25-12-04 | 181.98 $ | +0.68% | 1,246,342 |
| 25-12-03 | 180.75 $ | +0.32% | 1,845,129 |
| 25-12-02 | 180.18 $ | +1.35% | 1,866,647 |
| 25-12-01 | 177.78 $ | -2.37% | 1,947,020 |
Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIIB Stock
Select your edition
All financial news and data tailored to specific country editions
